NBIX - Neurocrine Biosciences, Inc.

106.46
-0.270   -0.254%

Share volume: 1,031,722
Last Updated: 04-28-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.12%

PREVIOUS CLOSE
CHG
CHG%
$106.73
-0.27
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
27%
Profitability 0%
Dept financing 38%
Liquidity 75%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0.66%
1 Month
-3.74%
3 Months
-29.35%
6 Months
-8.37%
1 Year
-23.35%
2 Year
2.35%
Key data
Stock price
$106.46
P/E Ratio 
40.49
DAY RANGE
$104.73 - $108.33
EPS 
$3.40
52 WEEK RANGE
$84.23 - $157.98
52 WEEK CHANGE
-$22.60
MARKET CAP 
13.820 B
YIELD 
N/A
SHARES OUTSTANDING 
100.976 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-05-2025
BETA 
0.55
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,477,660
AVERAGE 30 VOLUME 
$1,842,738
Company detail
CEO: Kevin C. Gorman
Region: US
Website: neurocrine.com
Employees: 1,200
IPO year: 1996
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Neurocrine Biosciences, Inc. discovers, develops, markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. Lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. Company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease.

Recent news
loading